Treatment of bacterial dysentery
AssigneeThe Governors of the University of Alberta
InventorsDavid R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Governors of the University of Alberta
InventorsDavid R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
Estimating the term…
Compounds which bind to shiga-like toxins (SLT) associated with enteric E. coli infection, compositions including the compounds, methods for the neutralization of (SLT) in a patient, and methods for the diagnosis of enteric E. coli infection are disclosed. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to two or three di- or tri-saccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the di- and tri-saccharides is responsible for the increased binding affinity of the compounds relative to the di- and tri-saccharides themselves. The compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).
A compound of the following structure:
Dependencies are inferred from the claim text.